Ireland Promotes Dublin As ‘Natural Destination For EMA’ After Brexit
Executive Summary
Ireland is promoting Dublin as the new natural home of the European Medicines Agency when the agency relocates from London after Brexit. It cites the “excellent existing relationship” the country’s regulator, the HPRA, has with the EMA and with the broader EU medicines regulatory network, and the fact that the HPRA doesn’t only regulate medicines.
You may also be interested in...
Irish Health Minister Speaks About EMA Relocation, Drug Pricing, and Boosting Biosimilars
Dublin will “absolutely” meet the criteria for hosting the European Medicines Agency, says Irish health minister Simon Harris. The minister has also outlined his department’s approach to high drug pricing and says he expects a national biosimilars policy by the end of the year.
Irish Health Minister Speaks About EMA Relocation, Drug Pricing, and Boosting Biosimilars
Dublin will “absolutely” meet the criteria for hosting the European Medicines Agency, says Irish health minister Simon Harris. The minister has also outlined his department’s approach to high drug pricing and says he expects a national biosimilars policy by the end of the year.
Suspense Continues Over Formal EMA Hosting Criteria, October Decision On New Home Likely
The criteria for cities wanting to host the European Medicines Agency post Brexit should be formally agreed in June and the agency’s new location could be decided in October. There are concerns that, if the decision is left any longer, it will be hard for the EMA to move in the time remaining before the UK leaves the EU.